Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Shan Chen and Mingtao Zeng
Bacillus anthracis a Category A agent with the potential to be used in a large-scale bioterrorism attack. The current vaccine, known as Anthrax Vaccine Adsorbed (AVA), consists of a culture filtrate from an attenuated strain adsorbed to aluminum salts as an adjuvant. Although considered to be safe and effective, it is difficult to produce large amounts within a short time frame. Thus, there exists a need to produce a new-generation vaccine against anthrax that can be produced quickly. In order for the new candidate vaccines to be effective, they must elicit a high titer of antibodies against protective antigen (PA). PA neutralization minimizes host susceptibility to anthrax toxemia. In addition, eliciting antibodies against additional virulence factors, such as capsule antigens of B. anthracis, may enhance clearance of pathogen from host. This review will discuss the history of bioterrorism and current vaccine development against anthrax. To date, there have been advances in vaccine design that utilize manipulated spores, modified protein subunits, conjugated vaccines and viral delivery vehicles. Utilizing one or more of these advances may provide a new, better vaccine against anthrax.